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Results: 9 patients in the NC group were included (78±8 y). Serum
creatinine was 204±72μmol/L (clearance 34.2±17ml/min). CG included
10 patients (69,8±7 y, serum creatinine 98.7±23μmol/L). CRT implantation
was successful in 8/9 patients (88.9%) without contrast injection. Patient 9
was finally implanted with CS opacification after failure of the NC technique.
Mean procedure time and fluoroscopy time were similar in the two groups:
146±26 in the NC group versus 157±25 min (p = 0.34) and 24.8±15 in the NC
group versus 24.5±20 min (p = 0.96) respectively. Mean CS lead implantation
time was 45±21 (NC group) versus 37±12 min (p = 0.24). No major proce-
dure-related complications were observed in both groups.
Conclusion: CRT implantation is feasible in the majority of the cases
(88.9%) without contrast injection and without lengthening procedure time in
patients with RI. 
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Objective: Atrial fibrillation (AF) is a common arrhythmia associated with
increased risk of thromboembolic events or other complications. The French ran-
domized, multicenter, SETAM trial assessed the impact of the home monitoring
(HM) technology on detection and treatment of supra-ventricular arrhythmia
(SVA).
Methods: Patients (pts) implanted with a dual chamber pacemaker were
enrolled in the study at hospital discharge if they had a sinusal rhythm at enroll-
ment, no antiarrhythmic, anticoagulant or dual-antiplatelet therapy, and if they had
a CHA2DS2-VASc score of 2 or more. The pts were randomly assigned to an
active group (Act Gp), followed by Biotronik HM, or a control group (Cont Gp)
without HM surveillance. The time from implantation to the first SVA-related
intervention was compared between the 2 groups (primary endpoint).
Results: A total of 595 pts (mean age = 79±8 y.o, 63% male, mean
CHA2DS2-VASc score = 3.7±1.2) were followed during 12.8±3.3Mo. The
most prevalent co-morbidities were hypertension (82% pts), diabetes (29%)
and vascular disease (24%). Implantation indications were atrio-ventricular
blocks in 77% of pts, sinus node disease in 20% and others in 3%.The global
SVA incidence was 25% (29% in the Act Gp vs 22% in the Cont Gp, p=ns).
A therapy (drugs or ablation) was instituted for 49/291 pts (17%) in the Act
Gp vs 43/304 pts (14%) in the Cont Gp (p=ns). The median time from implan-
tation to the first therapy for SVA was 114 [44; 241] days in the Act Gp vs
224 [67; 366] days in the Cont Gp, representing a median gain of 110-days in
SVA management (50% reduction, p=0.01). Over these 92 pts, 54 had AF
(59%) and 38 had atrial flutter or tachyarrhythmia (41%). Anticoagulation was
initiated in 80% of pts and antiarrhythmic drugs in 55%.
Conclusion: The SETAM study demonstrated that HM allows earlier detection
and treatment of SVA in pacemaker pts. The next step is to report how early
detection of SVA with HM can possibly improve the patients clinical outcome.
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Aim: to evaluate routine French implanters strategy in device replacement
in patients under anticoagulation for atrial Fibrillation (AF pts). 
Method: A questionnaire was e-mailed to 140 French implanters.
Results: 102 aswers were obtained. In AF patients, admission is on day of
procedure D0 (10%) or D-1(80%) whether pts are on vitamine K antagonist
(VKA) or New Oral AntiCoagulant (NOAC). In AF pts under VKA, only 4%
bridge to Low Weight Heparine (LWH) or Unfractionated Heparine (UH)
while treatment is interrupted without substitution (wos) by 61% and
continued without interruption by 32%. In AF pts under NOAC, only 5%
bridge to UH or LWH while treatment is interrupted on D-3 (13%), D-2(25%),
D-1(44%). When interrupted, NOAC are resumed at D0 (23%), D+1(54%),
D+2(10%), D+3(3%).
Conclusions: Most of implanters hospitalize AF pts at D-1 of replacement
procedure. Short discontinuation (VKA, NOAC) or uninterruption (VKA) is
prefered to bridging strategy.
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Background: Approximately 1% of the adult population have heart failure
with reduced ejection fraction. Since the 1980s, therapeutic advances in this
field have been significant, particularly through the development of cardiac
resynchronization therapy (CRT). However, transvenous implantation of the
left ventricular (LV) lead is unsuccessful in 5 – 15% of patients. For this
group, surgical placement of LV lead is an alternative.
Objective: Compare the effects of transvenous versus surgical implantation
of the LV lead in CRT.
Methods: We included 100 consecutive patients who had received CRT in
our centre between January 2008 and July 2012 in a retrospective observa-
tional study. Twelve patients who had failed transvenous implantation of LV
lead had a surgical placement.
Results: Population characteristics were a mean age of 66±11 years, 16%
female, New York Heart Association class 2.9±0.5, 45% ischemic cardio-
myopathy, left ventricular ejection fraction (LVEF) 24±7%, QRS width
165±23ms. There were no major difference in preoperative variables between
two groups except sex category (12.5% female in transvenous group versus
42% in surgical group, p=0.022). During a mean follow-up of 508±429 days,
the improvements seen in all variables showed no difference between the
groups. At six months, 77% of patients had improved at least one class of their
dyspnea stage, LVEF improved significantly (24±7% versus 36±10% at
six months).
Conclusions: Surgical placement of LV lead offers similar benefits as
compared with transvenous implantation.
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Background: Electrical cardioversion (EC) is a major treatment of atrial
fibrillation (AF). External EC in patients with persistent AF is inefficient in
10-20% of the patients already pretreated with oral amiodarone. Patients
remain usually in permanent AF.
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This study aims to evaluate the efficacy of repeated external ± internal EC
in such patients. In case of persistent AF after a first external EC, a repeated
external EC was performed. After the inefficiency of 2 external EC, internal
cardioversion was perfomed.
Methods: Patients with persistent AF, after inefficient external EC and oral
pretreatment with amiodarone were included. After a mean of 3 months,
repeated external ± internal EC was proposed in order to recover sinus rhythm
(SR). These patients were compared with a control group, sex and age
matched, also treated with amiodarone but in whom the external EC was suc-
cessful at the first attempt.
The 2 groups were analyzed in a case-control study. We analyzed the rate
of successful external EC after the 2 procedures in the AF group. The recur-
rence rate of AF was analyzed after one year in both groups. 
Results: Twenty patients got unsuccessful external EC (mean age=64.1 years).
There were 40 patients in the control group (mean age=67.1 years). External EC
was repeated after a mean of 3.5±5.4 months. No patient needed internal EC.
After one year, there was no difference in the recurrence rate of AF in both groups
(35% vs. 27%; p=0.244, in studied and control groups, respectively).
Conclusion: Repeated external EC allows SR recovery in all the patients
with AF under long term oral amiodarone, after a first unsuccessful external
EC. The AF recurrence rate after one year was similar to patients in whom the
first attempt was successful at once. 
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Aim: of the study was to evaluate the possible existence of a nightmare
modulation of VTCL stability in ICD recipients.
Method: We evaluated 45 ICD pts with 104VT episodes occurred both at
day (80) and night (24) time in a FU period of 5±3years. As index of VTCL
stability we considered the coefficient of variance (CVRR=SD/Mean RRX100)
of the last 5-10 consecutive stored normal RR intervals prior to the VT.
Results: During day-night, the VTCL was 340±29ms and 352±45ms
(p=NS) and the CVRR was 2,83±0,52 and 3,36±0,68(p=0.017).
Conclusions: The VTCL is less stable during night compared to the day
time, in pts with DCM. A possible explanation is that, the sympathovagal
nightmare alteration modifies the electrophysiological properties of the
arrhythmogenic substrate. The clinical significance of this study is towards
programming the ICD parameters. 
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Introduction: Very narrow QRS has been described whose prevalence and
prognosis relevance in the normal population is unknown. 
Methods: 546 healthy men between 50 and 60 yo (group 1) and 373 similar
patients with coronary artery disease (368 men, EF < 50% in 40%) (group 2)
underwent signal averaged ECG allowing precise measurement of QRS dura-
tion. All cause mortality was determined after 17±3 years follow-up.
Results: Mean QRS duration was 97±13ms for group 1 and 103±16ms for
group 2. 85 group 1 subjects (16%) had QRS < 85ms and 23 (4%) had QRS
>120ms. 44 group 2 patients (12%) had QRS < 85ms and 44 (12%) had QRS
>120ms. QRS were larger in case of lower EF, lack of previous angioplasty
and multivessel disease. 
All cause mortality in group 1 was 10,4% (57/546): 6/85 in case of QRS
<85ms (7%) and 2/23 (9%) in case of QRS > 120ms (p=ns compared to
normal QRS duration). HR for all-cause mortality in case of QRS < 85ms was
0,75 (95% CI 0.32-1.76, p = 0,52) and 0,86 (95% CI 0.21-3.53, p = 0,84) for
QRS >120ms.
All cause mortality in group 2 was 29% (109/373): 7/44 in case of QRS
<85ms (16%) and 22/44 (50%) in case of QRS > 120ms (p=0.002 when com-
pared to normal QRS duration). Adjusted HR for all-cause mortality in case
of QRS < 85ms was 0,65 (95% CI 0.29-1.45, p = 0,29) and 1.73 (95% CI
1.02-2.94, p = 0,05) for QRS > 120ms. 
Late potentials (LP) were present in SA-ECG in 116 group 1 subjects
(21%). LP were present in 100 group 2 patients (27%) and were significantly
related to multivessel disease, altered EF, lack of revascularization or of
angioplasty. LP were more frequently observed in case of QRS > 120ms in
both groups. LP were nor related to all-cause mortality in both groups.
Conclusion: QRS “narrower than normal” (< 85ms) can be observed in a
significant porpotion of healthy males between 50 and 60 years old and in
similar patients with ischemic heart disease. In opposition to QRS > 120 msec
which are independantly related to a higher all-cause mortality in coronary
artery disease patients, QRS <85ms were not linked to prognosis in any group.
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Background: Following the exponential growth of cardiac device implanta-
tion, there is an increase of lead extraction indications. In the meantime, the tools,
the indications, and the outcomes of those procedures continue to progress.
Objectives: The purpose of this study was to examine contemporary indi-
cations, outcomes, and complications of transvenousleadextraction in a large
series of patients at a high-volume lead extraction center.
Methods: We performed a retrospective cohort study of consecutive
patients undergoing leadextraction at a single, high-volume center.Our extrac-
tion strategy consists in manual traction, locking stylet traction, laser use fol-
lowed by inferior approach in case of failure.
Patient and lead characteristics and the indications, outcomes, and need for
laser assistance were analyzed
Results: From January 2002 to December 2013, a total of 751 chronic
endovascular leads were removed from 391patients.The mean age was years
68 (range 13- 98). Seventy-five percent of patients were males. Median
implantation duration was 5,5 years. Indications for extraction were systemic
infection (33,3%), pocket infection (25,1%), mechanical lead failure (32,7%),
and upgrade of device system (6,1%)due to thrombosis of veinous access.
Extraction was successful in 97,7% of patients with complete removal.
Laser assistance for extraction wasrecquired in 259 patients (66,2%),
completed with an inferior approach in 38 patients(9,7%). Complications were
death in 2 patients (0,5%),bleeding in 21 patients (5,4%), pericardial tam-
ponade in 8 patients (2%).
In univariate analysis, laser-assisted lead extraction was required more fre-
quently for leads that were implanted more 36 months than others (p<0,001),
as well as for passive leads compared to active leads (p=0,04).
Conclusion: Lead extraction can be safely and succefully performed in the
majority of patients, with limited life-threatening complications.
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Introduction: More and more frequently, silent atrial fibrillation (AF)
events are detected in intracardiac electronic device (ICED) memory (“infra-
